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Abstract
The importance of optimal blood pressure control for preventing or reducing the impairment of vascular and cognitive functions is well
known. However, the reversibility of early alterations in vascular and cognitive functions through antihypertensive agents is under-
investigated. In this study, we evaluated the inﬂuence of 3 months of angiotensin-converting enzyme (ACE) inhibition treatment on the
morphological and functional arterial wall and cognitive performance changes in 30 newly diagnosed primary hypertensive patients.
Common carotid intima-media thickness (IMT) and brachial artery ﬂow-mediated dilatation (FMD) were detected by
ultrasonography. Arterial stiffness indicated by augmentation index (AIx) and pulse wave velocity (PWV) was assessed by
arteriography. Cognitive functions were assessed by neuropsychological examination.
The executive function overall score was signiﬁcantly higher at 3-month follow-up than at baseline (median, 0.233 (IQR, 0.447) vs –
0.038 (0.936); P= .001). Three-month ACE inhibition did not produce signiﬁcant improvement in IMT, FMD, AIx and PWV values.
Signiﬁcant negative associations were revealed between IMT and complex attention (r=–0.598, P= .0008), executive function (r=–
0.617, P= .0005), and immediate memory (r=–0.420, P= .026) overall scores at follow-up. AIx had signiﬁcant negative correlations
with complex attention (r=–0.568, P= .001), executive function (r=–0.374, P= .046), and immediate memory (r=–0.507, P= .005).
PWV correlated signiﬁcantly and negatively with complex attention (r=–0.490, P= .007).
Timely and effective antihypertensive therapy with ACE inhibitors has signiﬁcant beneﬁcial effects on cognitive performance in as
few as 3 months. Early ACE inhibition may have an important role in the reversal of initial impairments of cognitive function associated
with hypertension-induced vascular alterations.
Abbreviations: ABPM = 24-hour ambulatory blood pressure monitoring, ACE = angiotensin-converting enzyme, AIx =
augmentation index, ARB = angiotensin II receptor blocker, dBP = diastolic blood pressure, dHI = diastolic hyperbaric index, DSM-5
= Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, FMD = ﬂow-mediated dilatation, HDL = high-density
lipoprotein, hs-CRP= high-sensitivity C-reactive protein, HTC= hematocrit, IMT= intima-media thickness, IQR= interquartile range,
LDL = low-density lipoprotein, PWV = pulse wave velocity, RAAS = renin-angiotensin-aldosterone system, RBC = red blood cell,
sBP = systolic blood pressure, sHI = systolic hyperbaric index, Thr = thrombocyte, WBC = white blood cell.
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1. Introduction underlyingmechanismof atherosclerosis.[1]Hypertension is oneof
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Csikai et al. Medicine (2019) 98:34 Medicinedamage. Endothelial dysfunction is the initial pathophysiological
step invasculardamage.[3]Apreviousprospective study showed that
forearm endothelial dysfunction determined by FMD is highly
predictive for cardiovascular morbidity and future cardiovascular
events in initially untreated and uncomplicated subjects with
essential hypertension.[4] A dysfunctional endothelium may lose its
ability to protect the vascular system through a loss of its anti-
atherosclerotic and antithrombotic potential, thus playing a key
pathophysiological role in the development and progression of the
atherosclerotic process. Carotid IMT, a morphological characteris-
tic of the arterial wall, is considered to be a reliable marker of
preclinical atherosclerosis.[5] Carotid IMT correlates with the
severity of hypertension and its growth is a good indicator of
atherosclerosis progression.[6]Moreover, carotid IMT is apredictive
factor for future vascular events.[7] Arterial stiffness, a functional
arterial wall feature described via AIx and PWV, is an early sign of
atherosclerosis.[8] Increased arterial stiffness is an independent
predictor of cardiovascular events and all-cause mortality.[9]
The impact of hypertension on vascular remodeling is a well-
known phenomenon, but consequential cognitive impairment has
been debated in the scientiﬁc literature. The American Heart
Association published a scientiﬁc statement in 2016 which stated
that there were insufﬁcient data to make evidence-based
recommendations.[10] However, the debate is far from over, as a
recently published systematic review speciﬁed the MoCA as the
recommended tool for differentiating vascular dementia from
vascular mild cognitive impairment.[11] Both publications empha-
sized the need for further research, with the following emphasis
from the 2016 AHA publication: “Antihypertensive drugs are
generally safe and widely available, but there is still much to be
learned about how to best use them over the life course in the
presenceof comorbidities andwhether speciﬁc classes ofdrugsmay
confer cognitive beneﬁts beyond BP lowering.”[10]
Substantial evidence supports a link between hypertension and
cognition.[12,13] This relationship might be mediated by vascular
system impairment. Hypertension disrupts the structure of
cerebral blood vessels, promotes atherosclerosis, and impairs
vital cerebrovascular regulatory mechanisms. Hypertension has
been associated with executive dysfunction, reduced mental
processing speed, and, less frequently, memory deﬁcits.[14]
Although cognitive impairment is well documented in people
with hypertension, little is known about the reversibility of
cognitive changes in this population.[13]
The renin-angiotensin-aldosterone system (RAAS) has a central
role in the pathophysiology of hypertension as well as cardio- and
cerebrovascular diseases evolving from atherosclerosis.[15,16] It is
well known that by blocking the RAAS, ACE inhibitors possess, in
addition to blood pressure-lowering effects, a vascular protective
and anti-ischemic action through their anti-atherosclerotic,
antithrombotic, and anti-inﬂammatory effects.[17,18] A previous
study has produced evidence that ACE inhibition is an emerging
potential modality of cognitive protection by minimizing irrevers-
ible brain and heart damage.[19] However, the inﬂuence of ACE
inhibition on the reversibility of initial atherosclerotic vascular
alterations and cognitive performance impairments induced by
early-stage hypertension is still under investigation. Therefore, in
this 3-month follow-up study,weaimed to evaluate the inﬂuenceof
ACE inhibitors on early morphological and functional changes of
the arterial wall and cognitive performance impairments in newly
diagnosed primary hypertensive patients. We also investigated the
associations between initial atherosclerotic arterialwall alterations
and cognitive function parameters.22. Methods
2.1. Patients
From January 2014 to January 2017, 59 patients with recently
diagnosed primary hypertension were recruited into our baseline
investigations (Fig. 1). No participants were on antihypertensive
treatment at baseline measurements. After baseline investiga-
tions, antihypertensive monotherapy was commenced with an
angiotensin-converting enzyme inhibitor (enalapril or lisinopril).
Twenty-nine patients had been excluded from the study
secondary to non-compliance or switching from ACE inhibitor
therapy to another antihypertensive agent due to side effects or
inefﬁcacy. Hence, the ﬁnal data analysis involved 30 patients
(age: 43.60±11.34 years; male/female ratio: 2.0, body mass
index: 27.81±4.04kg/m2) who completed the follow-up visit at
three months. No subjects were pregnant or suffered from
malignancy, impaired liver or renal function, alcohol or drug
dependence, infectious diseases, or symptomatic cerebro- or
cardiovascular diseases as observed through medical history,
general physical and neurological examination, routine labora-
tory tests, and cerebral computed tomography scan. There were 5
smokers among the study participants. Thirty percent of patients
had higher education. The study protocol was approved by the
Ethics Committee of the University of Debrecen and the study
was carried out in accordance with the Declaration of Helsinki.
All participants gave written informed consent.
2.2. Laboratory assays
Venous blood samples were collected after overnight fasting.
Serum ions, basic kidney functions, glucose levels, lipid proﬁle,
and complete blood count were assayed by routine automated
laboratory methods. High-sensitivity C-reactive protein was
assessed by turbidimetric assay on an Integra 800 analyzer
(Roche Diagnostics, Mannheim, Germany). Hemoglobin A1C
was measured by high-performance liquid chromatography
(BioRad, Hercules, CA). Fibrinogen concentration was deter-
mined by the Clauss method.2.3. Ambulatory blood pressure monitoring
Twenty-four-hour ambulatory blood pressure monitoring (ABPM)
was performed using the ABPM-04 device (Meditech Ltd., Buda-
pest, Hungary). Blood pressure was recorded every 15 minutes
during the daytime (6 AM through 10 PM) and every 30 minutes
during nighttime (10 PM through 6 AM). Based onABPMdata, mean
systolic and diastolic blood pressures and systolic and diastolic
hyperbaric indices for daytime and nighttime were determined.2.4. Common carotid intima-media thickness
measurement
Philips HD 11 XE ultrasound equipment with a 7.5-MHz linear
transducer was used to measure common carotid intima-media
thickness (IMT). Online measurements of IMT were performed in
the far arterywall of the common carotid arteries, 10mmproximal
to the carotid bulb. IMT was determined as the distance between
the lumen-intima interface and the upper layer of the adventitia. All
measurements were performed on frozen, enlarged images at end-
diastole, with the transducer in the mediolateral direction. Ten
measurements of IMTwere performed on both sides. The mean of
the 20 IMT values in each patient was calculated.
Excluded (n = 12) 
♦ Not meeting inclusion criteria (n = 8) 
♦ Declined to participate (n = 4) 
Analysed (n≤ 30)  
♦ Exclusion from analysis in case of 
artefact or missing data is possible
Lost to follow-up (n = 29) 
♦ Excluded due to non-compliance (n = 15) 
♦ Switching to another antihypertensive agent (n = 8) 
♦ Other reasons (n = 6)
Baseline 
Analysis 
Follow-Up
Enrollment 
Assessed for eligibility (n = 71) 
Confirmed eligible (n = 59) 
Recruited into baseline investigations (n = 59) 
Completing 3-month follow-up (n = 30) 
♦ Enalapril (n = 15) 
♦ Lisinopril (n = 15) 
Commenced antihypertensive monotherapy (n = 59) 
Figure 1. Flow diagram of the study.
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Brachial artery ﬂow-mediated dilatation (FMD) assessment was
performed using the HP Sonos 5500 ultrasound with 10-MHz
linear assay transducer. A B-mode longitudinal section was
obtained from the brachial artery above the antecubital fossa. A
forearm cuff was inﬂated to supra-systolic pressures for 5minutes
to induce arterial occlusion. Upon cuff release, the induced
reactive hyperemia promotes an increase in shear stress-mediated
NO release and subsequent vasodilation. FMD is expressed as the3percent increase in arterial diameter following cuff release with
the arterial diameter at baseline as reference.2.6. Assessment of arterial stiffness
Measurements were carried out using a TensioClinic arterio-
graph (TensioMed Ltd., Hungary). Arterial stiffness was assessed
by determining the augmentation index (AIx) and pulse wave
velocity (PWV). The method is based on the phenomenon of
Csikai et al. Medicine (2019) 98:34 Medicinemyocardial contractions generating pulse waves in the aorta. The
pulse wave travels to the arm (ﬁrst wave), where the cuff is
located, then back to the aorta. The ﬁrst wave is reﬂected at the
bifurcation of the aortic wall; therefore, a second, reﬂected wave
appears as a late systolic peak. The cuff detects both pulse waves.
AIx is calculated from the amplitudes of the ﬁrst and second wave
and represents the pressure difference between the late systolic
peak and the early systolic peak divided by the pulse pressure.
PWV is the ratio of the jugular fossa–symphysis distance and the
reﬂection time at 35-mmHg suprasystolic pressure on the
brachial artery.Table 1
Laboratory parameters of study participants.
Parameters Baseline 3-month follow-up P value
Na+ (mM)
∗
140.3 (2.20)
(n=27)
140.1 (2.80)
(n=29)
.721
(n=26)
K+ (mM)
∗
4.30 (0.295)
(n=27)
4.50 (0.260)
(n=29)
.009
(n=26)
Blood urea nitrogen (mM)
∗
5.22 (1.32)
(n=29)
5.02 (1.57)
(n=29)
.480
(n=28)2.7. Neuropsychological assessment
All patients underwent a comprehensive 1.5-hour long neuro-
psychological examination carried out and evaluated by trained
psychologists. The test battery was composed speciﬁcally for the
determination of the main neurocognitive functions as listed by
the Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5): reaction time, attention, executive function,
learning, memory, and perceptual-motor skills. The battery
included the most sensitive tests to reveal minor cognitive
function deviations, which are not necessarily evident during
everyday activity. The categorization shown in Table 3 was used
to assign each test of the battery to 1 of 3 neuropsychological
domains of importance in hypertension-related cognitive im-
pairment.
Because anxiety and depression assessment is a basic
requirement in neurocognitive examination, the subjects ﬁlled
out the State-Trait Anxiety Inventory and the Beck Depression
Inventory; this enabled us to also examine if higher levels of these
variables have a negative inﬂuence on performance.Creatinine (mM)
∗
79.3 (16.8)
(n=29)
76.0 (15.5)
(n=29)
.066
(n=28)
Fasting glucose (mM)† 5.0 / 0.80
(n=29)
5.10 / 0.60
(n=29)
.088
(n=28)
Hemoglobin A1c (%)
∗
5.20 (0.418)
(n=16)
5.22 (0.410)
(n=19)
.601
(n=16)
Total cholesterol (mM)† 5.0 / 1.10
(n=29)
5.10 / 1.40
(n=29)
.153
(n=28)
HDL-cholesterol (mM)† 1.30 / 0.40
(n=27)
1.40 / 0.665
(n=28)
.217
(n=25)
LDL-cholesterol (mM)
∗
3.20 (0.882)
(n=26)
3.50 (1.064)
(n=28)
.245
(n=24)
Triglyceride (mM)† 1.30 / 0.80
(n=29)
1.0 / 0.80
(n=29)
.300
(n=28)
hs-CRP (mg/l)† 1.50/3.0
(n=29)
1.80/2.85
(n=28)
.636
(n=27)
Fibrinogen (g/l)
∗
2.88 (0.616) 3.01 (0.719) .3132.8. Statistical analysis
Statistical analysis was performed using Stata version 15
(StataCorp LLC, College Station, TX). P< .05 was regarded as
statistically signiﬁcant. Baseline and follow-up levels of variables
were described using standard statistics and compared using
paired t tests if normality assumptions were satisﬁed, or
Wilcoxon matched-pairs signed-ranks tests otherwise. Location
and variability parameters mentioned in the body text are given
as mean ± standard deviation or median (interquartile range).
Overall scores for each neuropsychological domain were
derived by direction-correcting each variable in the domain (i.e.,
multiplying by negative 1 if necessary, so that greater values
represent better performance), standardizing them, and taking
their average.(n=26) (n=27) (n=24)
WBC (G/l)
∗
6.58 (1.78)
(n=29)
6.74 (1.75)
(n=29)
.358
(n=28)
RBC (T/l)
∗
4.94 (0.436)
(n=29)
4.91 (0.471)
(n=29)
.748
(n=28)
Hemoglobin (g/l)
∗
147.8 (13.86)
(n=29)
146.7 (14.2)
(n=29)
.991
(n=28)
Hematocrit
∗
0.436 (0.037)
(n=29)
0.432 (0.038)
(n=29)
.387
(n=28)
Thrombocyte (G/l)
∗
236.7 (51.21)
(n=29)
234.7 (39.4)
(n=29)
.910
(n=28)
HDL=high-density lipoprotein, hs-CRP=high-sensitivity C-reactive protein, LDL= low-density
lipoprotein, RBC= red blood cell, WBC=white blood cell.
∗
Paired t test: data expressed as mean (SD).
†Wilcoxon matched-pairs signed-ranks test: data expressed as median / interquartile range.2.9. Correlation estimates were based on Pearson’s
correlation coefﬁcient
Associations between clinical data and neuropsychological
outcomes were evaluated using linear regression. The outcome
variable was additive change from baseline to follow-up in the
neuropsychological parameter. Explanatory variables included
baseline value and additive change in the clinical variable (key
explanatory variables), an interaction term between them, age,
sex, and baseline of the neuropsychological parameter. Model-
predicted outcomes were plotted as a function of the key
explanatory variables to assess which combination of the latter
was predictive of signiﬁcant changes in the outcome. Statistical4proof for the relevance of the clinical parameter was interpreted
through the joint P value associated with the key variable pair
(general indication of relevance) as well as through the P value
associated with the interaction term (indicating an interplay
between baseline and change, i.e., a positive change from a low
baseline has a different effect than one from an already high
baseline, and likewise for negative changes).3. Results
3.1. Laboratory and ABPM data
The laboratory characteristics of study participants at baseline
and after 3 months of ACE inhibitor therapy are summarized in
Table 1. There were no signiﬁcant differences at 3-month follow-
up compared to baseline in traditional vascular risk parameters,
renal function, or complete blood count. ABPM data are
demonstrated in Table 2. ABPM revealed a signiﬁcant decrease
in systolic and diastolic blood pressures and in systolic hyperbaric
index for both active (daytime) and passive (nighttime)
evaluations. However, no signiﬁcant differences were detected
between baseline and follow up in daytime or nighttime diastolic
hyperbaric index.
Table 2
Ambulatory blood pressure monitoring data.
Parameters Active (daytime) Passive (nighttime)
baseline
(n=27)
follow-up
(n=24)
p-value
(n=22)
baseline
(n=27)
follow-up
(n=24)
P value
(n=22)
sBP (mmHg) 144.6 (9.04)
∗
135.3 (8.21)
∗
.0003 129.0 (12.75)
∗
119.8 (10.91)
∗
.002
dBP (mmHg) 89.04 (5.67)
∗
82.13 (5.75)
∗
.0001 76 / 17† 69.5 / 12† .001
sHI (mmHgxh/24h) 332 / 191† 266 / 102.5† .049 347.8 (197.9)
∗
244 (139.1)
∗
.017
dHI (mmHgxh/24h) 218 / 104† 170 / 132.5† .810 204 / 185† 164 / 192.5† .487
dBP=diastolic blood pressure, dHI=diastolic hyperbaric index, sBP= systolic blood pressure, sHI= systolic hyperbaric index.
∗
Paired t test: data expressed as mean (SD).
†Wilcoxon matched-pairs signed-ranks test: data expressed as median / interquartile range.
Csikai et al. Medicine (2019) 98:34 www.md-journal.com3.2. Arterial wall morphology and functional
characteristics
No signiﬁcant decrease in the IMT value was observed after 3
months of ACEI therapy (0.55±0.10mm at baseline vs 0.54±
0.08mm at follow-up, P = .125). There was no signiﬁcant
increase in the FMD value after 3-month ACE inhibition (7.52±
2.21% at baseline vs 8.12±2.60% at follow-up, P= .393).
Arterial stiffness parameters also did not differ signiﬁcantly
between baseline and 3-month follow-up (AIx: –17.47±34.44%
vs –23.09±34.32%, P= .078; PWV: 9.3±2.40m/s vs 9.0±2.04
m/s, P= .141).
3.3. Neuropsychological tests and questionnaires
The neuropsychological test results are given in Table 3. After
three months of ACEI therapy, signiﬁcant improvement was
revealed in executive function (–0.038 (0.936) vs 0.233 (0.447);
P= .001); study patients had a signiﬁcantly better performance in
visual ﬂuency (5-Point Test, 96.27 (11.76) vs 98.68 (5.26);
P= .009) and inhibition skills (Stroop Test Victoria Version, 2.0
(0.533) vs 1.78 (0.444); P= .010). Complex attention and
immediate memory overall scores did not show a signiﬁcant
improvement from baseline to follow up. The study participantsTable 3
Neuropsychological tests and questionnaires (n=30).
Cognitive domains and psychological inventories
Measured functions Related neuropsycholo
Complex attention and reaction time (overall score)†
Selective reaction time
∗
Reaction time test (s)
Psychomotor pace, visuo-motor coordination† Digit symbol task (value score)
Divided and sustained attention† Toulouse-piéron test (performan
Processing speed† Stroop-test victoria version (Dot
Executive function (overall score)†
Inhibition skills, psychomotor pace† Stroop-test victoria version (colo
Shifting, psychomotor pace† Trail making test A and B (B-A
Visual ﬂuency, cognitive ﬂexibility† 5-Point test (performance score
Verbal working memory
∗
Digit span (backward score)
Spatial working memory† Corsi block-tapping test (backw
Immediate memory (overall score)
∗
Immediate verbal recall and memory† Rey auditory verbal learning tes
Immediate verbal recall† Digit span (forward score)
Spatial short term memory† Corsi block-tapping test (forwar
Spielberger state anxiety inventory (score)†
Spielberger trait anxiety inventory (score)
∗
Beck depression inventory (score)†
∗
Paired t test: data expressed as mean (SD).
†Wilcoxon matched-pairs signed-ranks test: data expressed as median / interquartile range.
5reached signiﬁcantly lower scores on the tests evaluating anxiety
(Spielberger State Anxiety Inventory, P= .016) and depression
(Beck Depression Inventory, P= .031) at follow-up compared to
baseline.
We analyzed the relationships between the morphological and
functional characteristics of the arterial wall and the parameters
of cognitive functions by Pearson correlation analysis. Signiﬁcant
negative correlations were identiﬁed between IMT and complex
attention (r=–0.482, P= .008 at baseline; r=–0.598, P= .0008
at follow-up), executive function (r=–0.420, P= .006 at baseline;
r=–0.617, P= .0005 at follow-up) and immediate memory (r=–
0.420, P= .026 at follow-up) overall scores. AIx had signiﬁcant
and negative correlations with complex attention (r=–0.410,
P= .027 at baseline; r=–0.568, P= .001 at follow-up), executive
function (r=–0.441, P= .017 at baseline; r=–0.374, P= .046 at
follow-up), and immediate memory (r=–0.507, P= .005 at
follow-up) overall scores. Signiﬁcant and negative univariate
correlation of PWV with complex attention overall score at
follow up (r=–0.490, P= .007) was found, but a positive
association of PWV with state anxiety score at follow-up (r=
0.397, P= .035) was detected.
FMD was correlated signiﬁcantly and negatively with
Spielberger Trait Anxiety score at baseline (r=–0.606, P= .001).Baseline 3-months follow-up P valuegical tests
–0.013 / 1.01 0.158 / 0.764 .074
0.659 (0.094) 0.630 (0.084) .052
16 / 4 15 / 4 .334
ce score, %) 97.18 / 3.12 97.86 / 4.43 .524
s time, s) 12 / 3 12 / 5 .630
–0.038 / 0.936 0.233 / 0.447 .001
rs/dots time ratio) 2.0 / 0.533 1.78 / 0.444 .010
score) 43 / 47 40.5 / 24 .064
, %) 96.27 / 11.76 98.68 / 5.26 .009
4.73 (1.46) 4.87 (1.17) .595
ard score) 5.5 / 2 6 / 1 .138
0.044 (0.638) 0.065 (0.769) .812
t (score) 7 / 2 6.5 / 1 .873
6.20 / 1.16 6.23 / 1.25 .884
d score) 5.5 / 1 6 / 1 .515
35.0 / 10 32.5 / 5 .016
44.17 (8.42) 41.70 (9.68) .077
4.0 / 5 2.5 / 6 .031
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neurocognitive performance overall test scores, systolic blood
pressure correlated signiﬁcantly and negatively with immediate
memory overall score at baseline (r=–0.409, P= .034). Further-
more, the systolic hyperbaric index had signiﬁcant and negative
relationships with immediate memory overall score (r=–0.436,
P= .023) and executive function overall score (r=–0.475,
P= .012) at baseline.
Analyzing the associations of anxiety and depression levels
with overall test scores, state anxiety showed signiﬁcant and
negative correlations with immediate memory at baseline (r=–
0.413, P= .023) and executive function at follow up (r=–0.398,
P= .030).
The improvement in executive function overall score were
associated with baseline thrombocyte count and change in
thrombocyte count (joint effect P= .006 and interaction P= .023)
presented in Figure 2(A), with baseline hematocrit values and
change in hematocrit values (joint effect P= .023, interaction
P= .012) presented in Figure 2(B), and also with baseline red
blood cell count and change in red blood cell count (joint effect
P= .024, interaction P= .005) presented in Figure 2(C).
4. Discussion
Since many of the more advanced vascular lesions in hyperten-
sion are not completely reversible, the importance of prevention,
early treatment, and more effective blood pressure control is
clearly demonstrated.[20,21] However, the crucial issue concern-
ing the reversibility of hypertension-induced early vascular
alterations and consequential changed cognitive functions
remained unanswered in critical aspects. By reducing the harmful
effects of angiotensin II, RAAS blockade with an ACE inhibitor
might provide a rational approach to reverse early hypertension-
induced vascular damage and cognitive alterations.[3,22] In this
follow-up study, we investigated the effects of three months of
ACE inhibition on hypertension-induced initial vascular and
cognitive changes.
Abnormal endothelial function, arterial stiffness, and carotid
media thickening have been implicated in the pathophysiology of
essential hypertension.[4,6,8] These morphological and functional
characteristics of vascular damage in hypertensive patients can be
detected with non-invasive techniques such as brachial FMD and
carotid IMT with ultrasound, and arterial stiffness parameters
(AIx, PWV) with arteriograph.
Miyamoto et al found that ACE inhibitor and angiotensin II
receptor blocker (ARB) antihypertensive treatment can improve
FMD-assessed endothelial dysfunction better than other drug
types.[23] In the present study, 3-month ACE inhibitor therapy
has not resulted in signiﬁcant changes in brachial artery FMD in
hypertensive patients. Blood pressure-related media thickening is
a manifestation of structural arterial wall remodeling in
hypertensive patients.[24] Puato et al showed that well-controlled
blood pressure levels can prevent pro-atherogenic carotid artery
remodeling.[25]
On the other hand, in the study by Ohta et al, carotid IMT
increased progressively in spite of well-controlled home blood
pressure values.[26] After vascular injury, a signiﬁcant amount of
early neointimal dendritic cells showed angiotensin-II receptor
expression. Tuleta et al found that even short-term ACE inhibitor
therapymay diminish remodeling processes in injured vessels by a
signiﬁcant reduction of neointimal growth.[27] Our research
group reported previously that 1-year antihypertensive therapy6results in signiﬁcant improvement in vascular wall structure
demonstrated by the reduction in carotid IMT.[28] In our present
study, the reductive effect of 3-month ACE inhibition on carotid
IMT did not reach a signiﬁcant level.
All classes of antihypertensive drugs might potentially decrease
arterial stiffness passively via the reduction of the distending
pressure.[29,30] Results from clinical and experimental studies
have suggested that activation of the RAASmay contribute to the
development of arterial stiffness, and RAAS blockade in patients
with hypertension has more pronounced effects on arterial
stiffness than other antihypertensive drugs.[31,32]Mallareddy et al
performed a meta-analysis of clinical trials investigating the
effects of ACE inhibitors on arterial stiffness measured by PWV
or AIx, and concluded that ACEI have modest beneﬁcial effects in
reducing arterial stiffness, and this effect is at least partly
independent of blood pressure changes.[33] In this study, ACE
inhibitor treatment for 3 months did not result in a signiﬁcant
decrease in arterial stiffness parameters.
Chronic arterial hypertension is a major contributor to
cognitive impairment.[34] The evidence to date points strongly
to a deleterious inﬂuence of midlife hypertension on cognitive
function in midlife and late-life. Executive function and
processing speed seem to be the cognitive domains most affected,
but memory can also be impaired.[13] Whereas cognitive
impairment is well documented in people with hypertension,
several key questions remain to be answered regarding the impact
of antihypertensive treatment on cognitive change in this
population.[13] After a long follow-up, an obvious beneﬁt of
antihypertensive therapy was demonstrated on cognitive func-
tions.[35] However, to date, there are limited data on the effect of
shorter-term antihypertensive treatment on cognitive functions.
In a study by Hanon et al, 6 months of ARB treatment, and in an
investigation by Hajjar et al, 1 year of ARB therapy resulted in
signiﬁcant cognitive function improvement.[36,37] Muldoon et al
reported that short-term treatment with various antihypertensive
drugs slightly improved working memory.[38] A previous
investigation by our study group showed that after 1 year of
appropriate and effective antihypertensive therapy, normalized
blood pressure was accompanied by an improved cognitive
performance.[28] Although some studies provided hints that
certain classes of antihypertensive drugs may be more effective
than others at improving cognition or reducing cognitive
decline,[39–41] most of these studies were underpowered or
without equivalent cognitive endpoints.[13] The current study
demonstrated that the applied short-term (3-month) antihyper-
tensive treatment with ACE inhibitors resulted in a signiﬁcant
improvement in executive function.
The association between hypertension and anxiety is well-
recognized.[42] However, the effect of antihypertensive treatment
on anxiety is less clear and still remains controversial. Muldoon
et al published that 6 weeks of antihypertensive treatment did not
affect anxiety in middle-aged hypertensive patients.[38] In
contrast, patients with early hypertension reached signiﬁcantly
lower anxiety levels in the previous investigation of our research
team after 1 year of antihypertensive therapy, and in this study
after three months of ACE inhibitor treatment. Previous data are
contradictory regarding the relationship between hypertension
and depression. Scalco et al reported earlier that hypertension
was associated with depression.[43] Conversely, a meta-analysis
of prospective cohort studies found no evidence that hyperten-
sion would be a risk factor for depression.[44] Recently, the RAAS
was proposed as being implicated in depression.[45] There is
Figure 2. Executive function overall score changes from baseline to follow-up as a function of changes in, and baseline levels of, thrombocyte count (A), hematocrit
(B), and red blood cell count (C). Marker labels indicate P value of model-predicted change at that location. HTC=hematocrit, NS=not signiﬁcant, RBC= red blood
cell, THR= thrombocyte.
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sant and antianxiety effects of drugs targeting the RAAS.[46–49]
Our data provide evidence that depression level after 3-month-
long ACE inhibition decreases signiﬁcantly in patients with newly
diagnosed hypertension.
Carotid intima-media thickness and arterial stiffness may serve
as risk markers for vascular cognitive impairments.[34] Previous
studies observed signiﬁcant inverse relationships of carotid IMT
and arterial stiffness with cognitive function.[34,50,51] In evaluat-
ing the associations of structural and functional artery character-
istics with cognitive parameters in hypertensive patients, we
found that carotid IMT and AIx correlated signiﬁcantly and
negatively with executive function, complex attention, and
immediate memory. Furthermore, PWV had a signiﬁcant
negative relationship with complex attention. Moreover, this
study has detected a signiﬁcant positive correlation between PWV
and anxiety, while FMD showed a signiﬁcant negative associa-
tion with anxiety. In addition, we established signiﬁcant negative
associations of anxiety with executive function and immediate
memory. Thus, our data provide further evidence that markers of
arterial wall alterations are closely associated with cognitive
function in hypertension.
As less evidence is available on the relationship between blood
cell count and cognitive function,[52–54] the current study
analyzed the associations between these parameters, trying to
provide relevant information about the impact of blood cell count
on cognitive performance. In the present investigation, for the
ﬁrst time in the literature, we have revealed signiﬁcant positive
associations of thrombocyte count, hematocrit, red blood cell
count, and their changes after 3-month ACE inhibition with
executive function in hypertensive patients. However, further
aspects remain to be explored in this ﬁeld.
A limitation of our study is the potential selection bias that
might exist due to the fact that the Department of Neurology was
recruiting untreated hypertensive patients for this study. In most
cases, hypertension is diagnosed in primary care in Hungary; this
study, however, involved patients referred to us by primary care
on suspicion of hypertension, which was to be conﬁrmed by our
team through a diagnostic workup (ambulatory BP monitoring
etc). Self-selection of patients included in the study is also possible
since more than half of eligible patients were lost during the
follow-up period. This results in a relatively small size of the study
sample, which limits the statistical power of our investigation;
however, the signiﬁcant improvement in cognitive alteration
caused by early hypertension-related vascular lesions underlines
the positive impact of ACE inhibition on vascular deteriorations
and consequential cognitive impairments. Furthermore, the
measurements of morphological and functional characteristics
of the arterial wall and the assessments of cognitive function
parameters were performed after a short period of ACE inhibitor
treatment. We, therefore, cannot provide information about
what duration of ACE inhibition is required for signiﬁcant
improvement to arterial wall alterations.5. Conclusion
In conclusion, timely and effective antihypertensive therapy with
ACE inhibitors for as short a period as 3 months was observed to
produce signiﬁcant improvements in cognitive performance
compromised by early hypertension-related vascular damage.
Our study suggests that ACE inhibitors might serve as a potential
agent for the reversal of cognitive alterations induced by initial8vascular damage associated with early-stage hypertension. As to
longer-term treatment, further prospective data are essential to
determine the duration of ACE inhibition required for signiﬁcant
improvement in early hypertension-related vascular damage.Acknowledgments
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